Characteristics and outcomes of T1a renal cell carcinoma presenting with metastasis.

Authors

null

Luke Wang

University of California San Diego, Department of Urology, La Jolla, CA

Luke Wang , Dhruv Puri , Franklin Liu , Sohail Dhanji , Margaret F Meagher , Aastha Shah , Saeed Ghassemzadeh , Juan Javier-Desloges , Aditya Bagrodia , Brent Shane Rose , James Don Murphy , Ithaar H Derweesh , Rana R. McKay

Organizations

University of California San Diego, Department of Urology, La Jolla, CA, Univeristy of California San Diego, Department of Urology, La Jolla, CA, University of California San Diego Health, La Jolla, CA, University of California, San Diego, La Jolla, CA

Research Funding

No funding received
None.

Background: T1a renal cell carcinoma (RCC) is associated with excellent cure rates. However, a small fraction present with metastasis. We sought to determine the clinical characteristics, variables associated with synchronous metastasis, and survival outcomes in patients with pT1a and cT1a RCC using the National Cancer Database (NCDB). We secondarily evaluated whether surgery impacted risk of all cause mortality in cT1a RCC with synchronous lung and bone metastasis. Methods: From 2004 to 2019, all cases of RCC in patients age ≥18 were extracted from NCDB. pT1a and cT1a RCC were characterized as those 1) with no metastasis at diagnosis, 2) with synchronous metastasis [pT1aNxM1 at diagnosis]. Impact of surgery on all cause mortality was not evaluated for cT1a with synchronous metastasis to liver and brain due to low sample sizes. Results: The table describes selected characteristics of the cohorts. On multivariable logistic regression, diagnosis of pT1a with synchronous metastasis was associated with age (OR 1.02), male sex (OR 1.64), tumor size (OR 1.84), cN1 (OR 1.08), sarcomatoid (OR 5.50), tumor grade (OR 2.84) (p<0.005 for these variables); and inversely with diagnosis in 2016-2019 (OR 0.66, p=0.044) and papillary histology (OR 0.45, p<0.001). On multivariable Cox regression of the cT1a cohort, ACM was associated with Charlson score (HR 1.50, p<0.001), metastasis to >1 site (HR 2.48, p=0.032), and inversely with radical (HR 0.42, p<0.001) and partial nephrectomy (HR 0.31, p<0.001). In cT1a with lung metastasis, partial (HR 0.06, p=0.049) and radical nephrectomy (HR 0.17, p=0.006) was inversely associated with ACM, while surgery of distant site was not. In cT1a with bone metastasis, partial (HR 0.21, p<0.001) and radical nephrectomy (HR 0.32, p<0.001) were the only variables inversely associated with ACM. 5-year overall survival for pT1a with synchronous metastasis is 39.4%; for cT1a with synchronous metastasis is 20.9%. Conclusions: Known prognostic features were associated with synchronous metastasis in T1a RCC. Surgical resection of primary site may impact risk of all cause mortality in select cases of synchronous metastatic disease.

pT1a RCC w/o mets
N=94,413 (99.6%)
pT1a RCC w/ synchronous mets
N=340 (0.4%)
p valuecT1a RCC w/o mets
N=84,795 (98.8%)
cT1a RCC w/ synchronous mets
N=1017 (1.2%)
p value
Age (IQR)59 (50, 67)64 (56, 71)<0.00160 (51, 68)66 (58, 74)<0.001
Male55,378 (59%)248 (73%)<0.00149,942 (59%)730 (72%)<0.001
Charlson 0-184,602 (90.0%)308 (90.0%)0.375282 (89%)871 (86%)0.14
Tumor size 4cm31,267 (33%)210 (62%)<0.00124,580 (29%)519 (51%)<0.001
Clear cell67,083 (71%)267 (79%)<0.00159,556 (70%)694 (68%)<0.001
Sarcomatoid 456 (0.5%)32 (9.4%)<0.001498 (0.6%)112 (11%)<0.001
No surgery of primary site----2,518 (3.0%)706 (69%)<0.001
Radical Nephrectomy29,459 (31%)227 (67%)20,050 (24%)186 (18%)<0.001
Dead at follow-up9,866 (10.4%)208 (61.2%)<0.001709 (69.7%)<0.001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Other

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 734)

DOI

10.1200/JCO.2023.41.6_suppl.734

Abstract #

734

Poster Bd #

L9

Abstract Disclosures

Similar Abstracts

First Author: Maxwell Sandberg

First Author: Sameh Hany Emile

First Author: Ryan Nasseri

Abstract

2023 ASCO Genitourinary Cancers Symposium

Creatinine to cystatin C ratio and mortality in renal cell carcinoma.

First Author: Benjamin Schmeusser